Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics is well-positioned to execute their CML Phase 3 program with ELVN-001, a next-generation ATP-competitive BCR-ABL TKI for chronic myeloid leukemia. With a positive update from the ongoing ENABLE study and FDA Fast Track Designation, the company continues to make progress towards study start in 2H26. Backed by a strong cash position of $895M and expected cash runway into 2030, our financial model reflects solid potential for positive returns, reinforcing our BUY rating and a price target of $78.

Bears say

Enliven Therapeutics is likely to face significant risks, including potential R&D, regulatory, and commercial setbacks, increased competition in the market, and insufficient product sales. Additionally, the company may need to rely on dilutive financing in the future, which could negatively impact financial performance. Based on a DCF-based valuation using a 11% discount rate and a 1.0% terminal growth rate, our price objective for the company is $65 per share, reflecting a total firm value of $3.66B. However, there are uncertainties and risks associated with ELVN-001's clinical development and potential approval, which could impact the company's stock performance.

ELVN has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 7 analysts, ELVN has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.